At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
Zilebesiran +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
In Brief
A Phase 2 clinical trial evaluating Zilebesiran and Placebo for Mild to Moderate Hypertension. Completed, enrolled 36 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild to Moderate Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
First PostedMay 2024
Enrollment StartJun 2024
Primary CompletionJul 2025
TodayJul 2026
First PostedMay 21, 2024
Enrollment StartJun 5, 2024
Primary CompletionJul 17, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.1 years ago
Interventions
Zilebesirandrug
Zilebesiran administered by subcutaneous (SC) injection
Placebodrug
Placebo administered by SC injection